template to identify aMOIs for submission to MATCHbox.

- Laboratory results of NGS assays done for clinical care will be the subject of this initiative. There is no funding for “screening” a patient for MATCH.
- Laboratories must notify NCI MATCH sites that the laboratory results would potentially allow the patient to be eligible for NCI MATCH.
- Laboratories must track how many assays per week detect rare variants that could make a patient eligible for NCI MATCH.
- If the clinician presents the MATCH study and the patient is eligible and desires to enter the study, the laboratory must agree to fill out a spreadsheet that can be used to put the results into the informatics system that assigns treatment in NCI MATCH (MATCHbox).
- Laboratories must have a way to answer questions from NCI MATCH sites about their assay and must have a contact person for optimal communication with the NCI MATCH team.
- Prior to participation, laboratories must enter into a collaboration agreement with NCI. A sample agreement is available upon request. As part of such a collaboration agreement, laboratories must agree to provide the licensing rights described in the CTEP IP Option to the Pharmaceutical Collaborators who provided agents for the NCI MATCH trial (https://ctep.cancer.gov/branches/rab/intellectual_property_option_to_collaborators.htm), as well as agree to the data sharing and publication rights consistent with those agreements.
- No reimbursement for these activities (testing or notification of sites of NCI MATCH eligibility) exists.
- Qualified laboratories serving underserved populations are encouraged to participate.

How to apply:
1. Submit Letter of interest (LOI) as described above under “Letter of Interest and Collaboration Agreement” to NCMATCHLabApps@nih.gov.
2. LOIs will be accepted until January 31, 2018 at 5:00 p.m. Eastern Time. LOIs will be reviewed on a monthly basis, with those arriving by the 15th day of the month being reviewed and answered by the 15th day of the following month.
3. Notification of acceptance, non-acceptance or questions from Steering Committee will be sent to the designated contact person as soon as the LOI has been reviewed. This notification will include further instructions if a full application is invited.

4. Applications that have not been submitted within 3 months of notification of acceptance will be de-activated, and a new LOI must then be submitted if the laboratory wishes to participate in NCI MATCH.
5. DO NOT send a full application until you are invited to do so.

Review criteria for LOI:
- Laboratory is a CLIA certified or accredited laboratory within the United States.
- Academic laboratories must have NCI MATCH open at their site.
- Laboratory has adequate sensitivity, specificity.
- Laboratory tests tumor tissue for rare variants as described in NCI MATCH.
- Laboratory agrees to provide needed information for evaluation of the analytical validity of the test.
- Laboratory is likely to refer at least 100 patients to NCI MATCH based on detection of rare variants in the past.
- Laboratory agrees to contact sites regarding NCI MATCH eligibility.
- Laboratory agrees to a collaboration with NCI as detailed above.

Review criteria for full application:
- Laboratory NGS assay interrogates inclusionary and all exclusionary variants for arms in which the laboratory will participate.
- Laboratory supplies evidence that the assay meets analytical requirements as detailed above.
- Laboratories are capable of contacting clinical sites, tracking activity, and of referring at least 100 patients to the study based on detection of rare variants in the past.
- Laboratories agree to execute a collaboration agreement with NCI, as well as to data sharing and sharing publication rights.
- Laboratories agree to abide by the procedures in place for the MATCH study and to collaborate fully with the MATCH team.

For more information, contact NCMATCHLabApps@nih.gov.


James V. Tricoli,
Chief, Diagnostic Biomarkers and Technology Development Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute.

[FR Doc. 2017–16203 Filed 8–1–17; 8:43 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2); notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c) (4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; Jun2017 Cycle 26 NExT SEP Committee Meeting.
Date: August 31, 2017.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Wing C, 6th Floor, Conference Room 10, Bethesda, MD 20892.
Contact Persons: Barbara Mroczkowski, Ph.D., Executive Secretary, Discovery Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20817 (301) 496–4291, mroczkoskib@mail.nih.gov. Toby Hecht, Ph.D., Executive Secretary, Development Experimental Therapeutics Program, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 3W110, Rockville, MD 20850, (240) 276–5683, toby.hecht@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Mampower; 93.399, Cancer Control, National Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; HIV-Related Comorbidities Systems Biology.

Date: August 25, 2017.

Time: 9:00 a.m. to 4:45 p.m.

Place: National Institutes of Health, 6701 Rockledge Drive, Suite 7180, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Tony L. Creazzo, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7180, Bethesda, MD 20892–7024, 301–827–7913, creazzotl@mail.nih.gov.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Opportunities for Collaborative Research at the NIH Clinical Center.

Date: August 30, 2017.

Time: 9:00 a.m. to 4:45 p.m.

Place: National Institutes of Health, 6701 Rockledge Drive, Room 7178, Bethesda, MD 20892–7024, 301–827–7938, johnsonw@nihki.nih.gov.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Advisory Committee for Women’s Services; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of a meeting of the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Advisory Committee for Women’s Services (ACWS) on August 10, 2017.

The meeting will include discussions on the role of SAMHSA’s Office of the Chief Medical Officer and emerging issues for women; a follow-up discussion on the Office of Women’s Health Report on Women and Opioids; the invisibility of American Indian/ American Native women; Legislative updates, including the Cures Act and the Comprehensive Addiction Recovery Act; and a conversation with the Deputy Assistant Secretary for Mental Health and Substance Use.

The meeting is open to the public and will be held at SAMHSA, 5600 Fishers Lane, Rockville, MD, 20857, in Conference Room 5E45. Attendance by the public will be limited to space available. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions should be forwarded to the contact person (below) by August 2, 2017. Five minutes will be allotted for each presentation.

The meeting may be accessed via telephone. To attend on site, obtain the call-in number and access code, submit written or brief oral comments, or request special accommodations for persons with disabilities, please register on-line at http://nac.samhsa.gov/Registration/meetingsRegistration.aspx, or communicate with SAMHSA’s Designated Federal Officer, Ms. Nadine Benton (see contact information below). Substantive meeting information and a roster of Committee members may be obtained either by accessing the SAMHSA Committees’ Web https://www.samhsa.gov/about-us/advisory-councils/meetings, or by contacting Ms. Benton.

Committee Name: Substance Abuse and Mental Health Services Administration Advisory Committee for Women’s Services (ACWS).

Date/Time/Type: Thursday, August 2, 2017, from: 9:00 a.m. to 4:45 p.m. EDT.

Place: SAMHSA, 5600 Fishers Lane, Conference Room 5N76, Rockville, Maryland 20857

Contact: Nadine Benton, Designated Federal Official, SAMHSA’s Advisory Committee for Women’s Services, 5600 Fishers Lane, Rockville, MD 20857, Telephone: (240) 276–0127, Fax: (240) 276–2252, Email: nadine.benton@samhsa.hhs.gov.

Brian Makela,
Chemist, Substance Abuse and Mental Health Services Administration.

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG–2017–0105]

Information Collection Request to Office of Management and Budget; OMB Control Number: 1625–0002

AGENCY: Coast Guard, DHS.

ACTION: Sixty-day notice requesting comments.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, the U.S. Coast Guard intends to submit an Information Collection Request (ICR) to the Office of Management and Budget (OMB), Office of Information and Regulatory Affairs (OIRA), requesting approval for reinstatement, without change, of the following collection of information: 1625–0002, Application for Vessel Inspection, Waiver, and Continuous Synopsis Record without change. Our ICR describes the information we seek to collect from the public. Before submitting this ICR to OIRA, the Coast Guard is inviting comments as described below.

DATES: Comments must reach the Coast Guard on or before October 2, 2017.

ADDRESSES: You may submit comments identified by Coast Guard docket number [USCG–2017–0105] to the Coast Guard using the Federal eRulemaking Portal at http://www.regulations.gov. See the “Public participation and request for comments” portion of the